Heron Therapeutics | HRTX - Debt


Heron Therapeutics reported $149.65M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amarin USD 0 0 Mar/2025
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
Eisai JPY 236.67B 49.14B Sep/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.62M 275K Mar/2026
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Omeros USD 442.16M 199K Sep/2023
Pacira USD 367.66M 4.53M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Surmodics USD 29.55M 111K Sep/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Veracyte USD 39.65M 799K Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026